Published in Br J Pharmacol on November 01, 2011
A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity. PLoS One (2012) 1.05
Methyl jasmonate abolishes the migration, invasion and angiogenesis of gastric cancer cells through down-regulation of matrix metalloproteinase 14. BMC Cancer (2013) 0.98
Methyl jasmonate sensitizes human bladder cancer cells to gambogic acid-induced apoptosis through down-regulation of EZH2 expression by miR-101. Br J Pharmacol (2014) 0.96
Molecular targets of TRAIL-sensitizing agents in colorectal cancer. Int J Mol Sci (2012) 0.91
Protective effect of caffeic acid on paclitaxel induced anti-proliferation and apoptosis of lung cancer cells involves NF-κB pathway. Int J Mol Sci (2012) 0.87
Survivin inhibitor YM-155 sensitizes tumor necrosis factor- related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathway. J Pharmacol Exp Ther (2013) 0.85
Metabolic interplay between glycolysis and mitochondrial oxidation: The reverse Warburg effect and its therapeutic implication. World J Biol Chem (2015) 0.85
Lactobacillus casei Exerts Anti-Proliferative Effects Accompanied by Apoptotic Cell Death and Up-Regulation of TRAIL in Colon Carcinoma Cells. PLoS One (2016) 0.82
Algae extracts and methyl jasmonate anti-cancer activities in prostate cancer: choreographers of 'the dance macabre'. Cancer Cell Int (2012) 0.82
Down-Regulation of Survivin by Nemadipine-A Sensitizes Cancer Cells to TRAIL-Induced Apoptosis. Biomol Ther (Seoul) (2013) 0.76
Wnt signaling and cancer. Genes Dev (2000) 18.53
Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell (1998) 13.87
A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A (1996) 11.37
Guide to Receptors and Channels (GRAC), 4th Edition. Br J Pharmacol (2009) 8.07
Colorectal cancer. Lancet (1999) 4.72
The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer (2008) 4.42
Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ (2003) 3.66
Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res (1998) 3.63
Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med (2002) 3.54
Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity (2000) 3.45
Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res (2001) 3.29
IAP-targeted therapies for cancer. Oncogene (2008) 3.09
To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest (2008) 3.05
FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity (2000) 2.99
TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol (2007) 2.49
Methyl jasmonate binds to and detaches mitochondria-bound hexokinase. Oncogene (2008) 2.34
Survivin and molecular pathogenesis of colorectal cancer. Lancet (2003) 2.25
Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ (2004) 2.17
Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol (2004) 1.90
The promise of TRAIL--potential and risks of a novel anticancer therapy. J Mol Med (Berl) (2007) 1.73
Human frizzled 1 interacts with transforming Wnts to transduce a TCF dependent transcriptional response. Oncogene (1999) 1.35
A mathematical approach to study combined effects of toxicants in vitro: evaluation of the Bliss independence criterion and the Loewe additivity model. Toxicol In Vitro (2007) 1.29
Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia (2002) 1.24
Epidemiology, treatment and chemoprevention in colorectal cancer. Ann Oncol (2003) 1.24
beta-Catenin signaling: therapeutic strategies in oncology. Cancer Biol Ther (2003) 1.21
Plant stress hormones suppress the proliferation and induce apoptosis in human cancer cells. Leukemia (2002) 1.16
Mitomycin C induces apoptosis and caspase-8 and -9 processing through a caspase-3 and Fas-independent pathway. Cell Death Differ (2002) 1.16
Jasmonates: novel anticancer agents acting directly and selectively on human cancer cell mitochondria. Cancer Res (2005) 1.15
Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updat (2005) 1.13
Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells. J Surg Res (2007) 1.11
Transcriptional and post-transcriptional controls of survivin in cancer cells: novel approaches for cancer treatment. J Exp Clin Cancer Res (2006) 1.09
Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis (2006) 1.06
Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells. Cancer Res (2006) 1.05
Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation. Cancer Res (2008) 1.04
FLIP protein and TRAIL-induced apoptosis. Vitam Horm (2004) 0.98
p53 gene mutations in early colorectal carcinoma. De novo vs. adenoma-carcinoma sequence. Int J Cancer (1995) 0.93
Sensitization of human colon cancer cells to TRAIL-mediated apoptosis. J Gastrointest Surg (2001) 0.92
Induction of differentiation of human myeloid leukemia cells by jasmonates, plant hormones. Leukemia (2004) 0.91
Effects of natural and novel synthetic jasmonates in experimental metastatic melanoma. Br J Pharmacol (2007) 0.90
Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis. Cancer Res (2005) 0.89
Aspirin enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation. Mol Pharmacol (2007) 0.86
ABC of colorectal cancer: adjuvant therapy. BMJ (2000) 0.82
Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole. Oncogene (2008) 0.80
Natural jasmonates of different structures suppress the growth of human neuroblastoma cell line SH-SY5Y and its mechanisms. Acta Pharmacol Sin (2008) 0.79
A global measure of perceived stress. J Health Soc Behav (1983) 56.90
Stress, social support, and the buffering hypothesis. Psychol Bull (1985) 19.28
Socioeconomic status and health. The challenge of the gradient. Am Psychol (1994) 13.59
Epidermal growth factor. Annu Rev Biochem (1979) 11.82
125I-labeled human epidermal growth factor. Binding, internalization, and degradation in human fibroblasts. J Cell Biol (1976) 10.88
Epidermal growth factor and a new derivative. Rapid isolation procedures and biological and chemical characterization. J Biol Chem (1972) 10.86
Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med (1997) 8.65
Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes. J Biol Chem (1980) 7.71
Beta Alanine as a Growth Accessory for the Diphtheria Bacillus. J Bacteriol (1937) 7.51
Visualization by fluorescence of the binding and internalization of epidermal growth factor in human carcinoma cells A-431. Proc Natl Acad Sci U S A (1978) 5.91
Direct visualization of the binding and internalization of a ferritin conjugate of epidermal growth factor in human carcinoma cells A-431. J Cell Biol (1979) 5.62
Does hiatus hernia affect competence of the gastroesophageal sphincter? N Engl J Med (1971) 5.44
Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J Biol Chem (1980) 5.19
Epidermal growth factor. J Biol Chem (1990) 4.79
Prophylactic vs therapeutic blood patch for obstetric patients with accidental dural puncture--a randomised controlled trial. Anaesthesia (2014) 4.75
IMMUNITY IN MUMPS : II. THE DEVELOPMENT OF COMPLEMENT-FIXING ANTIBODY AND DERMAL HYPERSENSITIVITY IN HUMAN BEINGS FOLLOWING MUMPS. J Exp Med (1945) 4.69
The primary structure of epidermal growth factor. J Biol Chem (1972) 4.41
Epidermal growth factor: morphological demonstration of binding, internalization, and lysosomal association in human fibroblasts. Proc Natl Acad Sci U S A (1978) 4.03
Human epidermal growth factor and the proliferation of human fibroblasts. J Cell Physiol (1976) 3.91
A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles. J Biol Chem (1982) 3.81
IN VITRO AND IN VIVO EFFECTS OF A NERVE GROWTH-STIMULATING AGENT ISOLATED FROM SNAKE VENOM. Proc Natl Acad Sci U S A (1956) 3.64
THE INFLUENCE OF PROTEIN INTAKE ON THE UREA CLEARANCE IN NORMAL MAN. J Clin Invest (1934) 3.60
Transformation by murine and feline sarcoma viruses specifically blocks binding of epidermal growth factor to cells. Nature (1976) 3.56
Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro. Nature (1978) 3.54
Hormone receptor topology and dynamics: morphological analysis using ferritin-labeled epidermal growth factor. Proc Natl Acad Sci U S A (1979) 3.54
Glycosyltransferase activity of Fringe modulates Notch-Delta interactions. Nature (2000) 3.51
Characterization of the binding of 125-I-labeled epidermal growth factor to human fibroblasts. J Biol Chem (1975) 3.48
Induction by EGF and interferon-gamma of tyrosine phosphorylated DNA binding proteins in mouse liver nuclei. Science (1993) 3.30
Heterogeneity of the peptide chains of gamma-globulin. Biochem J (1964) 3.25
Action of malarial antibody in vitro. Nature (1969) 3.24
Rapid enhancement of protein phosphorylation in A-431 cell membrane preparations by epidermal growth factor. J Biol Chem (1979) 3.18
Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med (1999) 3.10
Inhibition of membrane phosphotyrosyl-protein phosphatase activity by vanadate. Biochem Biophys Res Commun (1982) 3.01
ABC of intensive care. Withdrawal of treatment. BMJ (1999) 2.96
Human epidermal growth factor: isolation and chemical and biological properties. Proc Natl Acad Sci U S A (1975) 2.95
Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum (2003) 2.94
Social support and smoking cessation and maintenance. J Consult Clin Psychol (1986) 2.92
Rapid stimulation of pinocytosis in human carcinoma cells A-431 by epidermal growth factor. J Cell Biol (1979) 2.88
The production of migration inhibition factor by B and T cells of the guinea pig. J Exp Med (1973) 2.86
Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet (1999) 2.83
Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD merozoite antigen. Parasite Immunol (1988) 2.79
In vitro comparison of netilmicin, a semisynthetic derivative of sisomicin, and four other aminoglycoside antibiotics. Antimicrob Agents Chemother (1976) 2.75
Debunking myths about self-quitting. Evidence from 10 prospective studies of persons who attempt to quit smoking by themselves. Am Psychol (1989) 2.72
Properties of protective malarial antibody. Immunology (1970) 2.65
Rapid induction of morphological changes in human carcinoma cells A-431 by epidermal growth factors. J Cell Biol (1979) 2.61
Evidence for high-energy extraterrestrial neutrinos at the IceCube detector. Science (2013) 2.56
The Fab fragments of monoclonal IgG to a merozoite surface antigen inhibit Plasmodium knowlesi invasion of erythrocytes. Mol Biochem Parasitol (1984) 2.54
A simple technique to reduce the incidence of accidental dural puncture. Anaesthesia (2001) 2.53
Stress and immunity in humans: a meta-analytic review. Psychosom Med (1993) 2.52
Conjugational transfer of gentamicin resistance plasmids intra- and interspecifically in Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother (1983) 2.50
The distribution of antigenic and nonantigenic compounds within draining lymph nodes. Lab Invest (1966) 2.49
Identity and interspecific transfer of gentamicin-resistance plasmids in Staphylococcus aureus and Staphylococcus epidermidis. J Infect Dis (1980) 2.48
Enhancement of calcium uptake and phosphatidylinositol turnover by epidermal growth factor in A-431 cells. Biochemistry (1981) 2.46
Social support and adjustment to cancer: reconciling descriptive, correlational, and intervention research. Health Psychol (1996) 2.46
Nobel laureates' letter to President Bush. Washington Post (2001) 2.43
Inconsistent visual analyses of intrasubject data. J Appl Behav Anal (1979) 2.43
A merozoite vaccine effective against Plasmodium knowlesi malaria. Nature (1974) 2.39
Group support interventions for women with breast cancer: who benefits from what? Health Psychol (2000) 2.38
In vitro and in vivo activity of a lymphocyte and immune complex-dependent chemotactic factor for eosinophils. J Exp Med (1971) 2.36
Methyl jasmonate binds to and detaches mitochondria-bound hexokinase. Oncogene (2008) 2.34
Review of psychosocial stress and asthma: an integrated biopsychosocial approach. Thorax (1998) 2.33
Depression and immunity: a meta-analytic review. Psychol Bull (1993) 2.30
Investigation of benefits and costs of an ophthalmic outreach clinic in general practice. Br J Gen Pract (1995) 2.26
Absence of circular plasmid deoxyribonucleic acid attributable to a genetic determinant for methicillin resistance in Staphylococcus aureus. J Bacteriol (1973) 2.25
Bioengineered cardiac grafts: A new approach to repair the infarcted myocardium? Circulation (2000) 2.25
Our new President: Frank P. Brooks. Gastroenterology (1980) 2.24
Cytoplasmic pH regulation in thymic lymphocytes by an amiloride-sensitive Na+/H+ antiport. J Gen Physiol (1984) 2.23
In vitro isolation of Plasmodium knowlesi merozoites using polycarbonate sieves. Parasitology (1975) 2.23
Cimetidine in the treatment of symptomatic gastroesophageal reflux: a double blind controlled trial. Gastroenterology (1978) 2.21
Isolation of a calcium-dependent 35-kilodalton substrate for the epidermal growth factor receptor/kinase from A-431 cells. J Biol Chem (1984) 2.21
Merozoite vaccination against Plasmodium knowlesi malaria. Immunology (1975) 2.21
Overexpression of peptide-methionine sulfoxide reductase in Saccharomyces cerevisiae and human T cells provides them with high resistance to oxidative stress. Proc Natl Acad Sci U S A (1998) 2.19
Mesiotemporal T2-weighted hyperintensity: neurosyphilis mimicking herpes encephalitis. AJNR Am J Neuroradiol (2001) 2.16
Structure and biological properties of immunoglobulins. Adv Immunol (1967) 2.08
Hormonal regulation of human lower esophageal sphincter competence: interaction of gastrin and secretin. J Clin Invest (1971) 2.07
Colonic myoelectric activity in the irritable bowel syndrome. Gastroenterology (1976) 2.05
Constitutive penicillinase formation in Staphylococcus aureus owing to a mutation unlinked to the penicillinase plasmid. J Bacteriol (1968) 2.03
A merozoite receptor protein from Plasmodium knowlesi is highly conserved and distributed throughout Plasmodium. J Biol Chem (1990) 2.02
First observation of PeV-energy neutrinos with IceCube. Phys Rev Lett (2013) 2.00
Rat monoclonal antibodies which inhibit the in vitro multiplication of Plasmodium knowlesi. Clin Exp Immunol (1982) 1.97
Merozoite vaccination of douroucouli monkeys against falciparum malaria. Lancet (1977) 1.95
Effect of the prophage and penicillinase plasmid of the recipient strain upon the transduction and the stability of methicillin resistance in Staphylococcus aureus. J Bacteriol (1973) 1.92
Epidermal growth factor. Location of disulfide bonds. J Biol Chem (1973) 1.90
Affinity labeling of the protein kinase associated with the epidermal growth factor receptor in membrane vesicles from A431 cells. J Biol Chem (1982) 1.89
Leukotactic factors elaborated by virus-infected tissues. J Exp Med (1972) 1.89
Antigenic variation and protective immunity in Plasmodium knowlesi malaria. Immunology (1972) 1.89
Structural and phenotypic varieties of gentamicin resistance plasmids in hospital strains of Staphylococcus aureus and coagulase-negative staphylococci. Antimicrob Agents Chemother (1982) 1.89
Co-localization of 125I-epidermal growth factor and ferritin-low density lipoprotein in coated pits: a quantitative electron microscopic study in normal and mutant human fibroblasts. J Cell Biol (1982) 1.88
Interaction of epidermal growth factor (EGF) with cultured fibroblasts. Adv Metab Disord (1975) 1.88
Epidermal growth factor: effects of androgens and adrenergic agents. Endocrinology (1974) 1.87
Impact of sample type on rapid detection of influenza virus A by cytospin-enhanced immunofluorescence and membrane enzyme-linked immunosorbent assay. J Clin Microbiol (2000) 1.86
Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis (2008) 1.84
Women's recall of obstetric complications in south Kalimantan, Indonesia. Stud Fam Plann (1997) 1.82
Drug utilization in a newborn intensive care unit. J Pediatr (1976) 1.82
The EH and SH3 domain Ese proteins regulate endocytosis by linking to dynamin and Eps15. EMBO J (1999) 1.82
Mutations in prophage phi11 that impair the transducibility of their Staphylococcus aureus lysogens for methicillin resistance. J Bacteriol (1977) 1.78
The stimulation of epidermal proliferation by a specific protein (EGF). Dev Biol (1965) 1.78
Long-term effects of educational and peer discussion group interventions on adjustment to breast cancer. Health Psychol (2001) 1.77
Role of gastrin supersensitivity in the pathogenesis of lower esophageal sphincter hypertension in achalasia. J Clin Invest (1971) 1.77